This new treatment option can redefine how we approach RRMM treatment by giving healthcare providers a regimen with improvement in PFS and OS and a well-characterized safety profile
The company announced positive topline data from the Phase II ZUPREME-1 trial
Evogene said ChemPass AI was significantly expanded during 2025 through internal development and collaborations with Google Cloud
Gazyva/Gazyvaro outperformed placebo across all key and secondary endpoints
The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations
Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results
The trial met its primary endpoint, showing statistically significant improvements in Myasthenia Impairment Index (MGII) Patient-Reported Outcome (PRO) ocular scores at Week 4
The system also introduces Imaging Scanner Interface 2 (ISI2) capability, enabling direct communication between injector and scanner to improve exam coordination and operational efficiency
The inspection concluded with zero observations, confirming the facility's compliance with current Good Manufacturing Practices
Hyderabad emerged as Lonza’s preferred destination after an extensive global evaluation process
Subscribe To Our Newsletter & Stay Updated
